This Securities Purchase Agreement (this “Agreement”) is entered into and made effective as of September 23, 2026, by and among HCW Biologics Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages ...
On September 9, 2026, HCW Biologics Inc. issued Amendment No. 1 to Preliminary Proxy Statement, a copy of which is included in this Form 8-K as Exhibit 10.1.
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
